Inclusion Criteria:~1. The patient (or if applicable the legally acceptable representative if different from
the responsible caregiver) and the responsible caregiver have signed the Informed Consent Form.~2. The patient
has probable AD, diagnosed according to National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.~3. The patient is
a man or woman, aged ≤ 85 years.~4. The patient has a Clinical Dementia Rating (CDR) total score of 0.5 or 1
(mild) and MMSE score of 20-26 (inclusive) at Screening.~5. Has at least one identified adult caregiver who is
able to provide meaningful assessment of changes in subject behavior and function over time and provide
information on safety and tolerability, and is able to verify daily compliance with study drug~6. The patient
has been treated with acetylcholinesterase inhibitor (AChEI), i.e., donepezil, galantamine, or rivastigmine, at
the time of Screening~ * For at least 3 months~ * The current dosage regimen and must have remained stable for
≥ 8 weeks~ * It must be planned that the dosage regimen will remain stable throughout participation in the
study~
